Literature DB >> 21741354

Pulmonary surfactant proteins and polymer combinations reduce surfactant inhibition by serum.

Karen W Lu1, Jesús Pérez-Gil, Mercedes Echaide, H William Taeusch.   

Abstract

Acute respiratory distress syndrome (ARDS) is an inflammatory condition that can be associated with capillary leak of serum into alveoli causing inactivation of surfactant. Resistance to inactivation is affected by types and concentrations of surfactant proteins, lipids, and polymers. Our aim was to investigate the effects of different combinations of these three components. A simple lipid mixture (DPPC/POPG) or a more complex lipid mixture (DPPC/POPC/POPG/cholesterol) was used. Native surfactant proteins SP-B and SP-C obtained from pig lung lavage were added either singly or combined at two concentrations. Also, non-ionic polymers polyethylene glycol and dextran and the anionic polymer hyaluronan were added either singly or in pairs with hyaluronan included. Non-ionic polymers work by different mechanisms than anionic polymers, thus the purpose of placing them together in the same surfactant mixture was to evaluate if the combination would show enhanced beneficial effects. The resulting surfactant mixtures were studied in the presence or absence of serum. A modified bubble surfactometer was used to evaluate surface activities. Mixtures that included both SP-B and SP-C plus hyaluronan and either dextran or polyethylene glycol were found to be the most resistant to inhibition by serum. These mixtures, as well as some with either SP-B or SP-C with combined polymers were as or more resistant to inactivation than native surfactant. These results suggest that improved formulations of lung surfactants are possible and may be useful in reducing some types of surfactant inactivation in treating lung injuries.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741354      PMCID: PMC3156878          DOI: 10.1016/j.bbamem.2011.06.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  44 in total

1.  Stress and fold localization in thin elastic membranes.

Authors:  Luka Pocivavsek; Robert Dellsy; Andrew Kern; Sebastián Johnson; Binhua Lin; Ka Yee C Lee; Enrique Cerda
Journal:  Science       Date:  2008-05-16       Impact factor: 47.728

2.  Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin-induced inactivation.

Authors:  Yi Y Zuo; Hamdi Alolabi; Arash Shafiei; Ningxi Kang; Zdenka Policova; Peter N Cox; Edgar Acosta; Michael L Hair; A Wilhelm Neumann
Journal:  Pediatr Res       Date:  2006-08       Impact factor: 3.756

Review 3.  Synthetic pulmonary surfactant preparations: new developments and future trends.

Authors:  Ismael Mingarro; Dunja Lukovic; Marçal Vilar; Jesús Pérez-Gil
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome.

Authors:  Andrea Calkovska; Daniela Mokra; Anna Drgova; Ivan Zila; Kamil Javorka
Journal:  Eur J Pediatr       Date:  2007-10-19       Impact factor: 3.183

5.  Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndrome.

Authors:  Andreas Almlén; Guido Stichtenoth; Bim Linderholm; Marie Haegerstrand-Björkman; Bengt Robertson; Jan Johansson; Tore Curstedt
Journal:  J Appl Physiol (1985)       Date:  2008-02-14

6.  Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro.

Authors:  Guido Stichtenoth; Philipp Jung; Gabi Walter; Jan Johansson; Bengt Robertson; Tore Curstedt; Egbert Herting
Journal:  Pediatr Res       Date:  2006-03       Impact factor: 3.756

Review 7.  Current perspectives in pulmonary surfactant--inhibition, enhancement and evaluation.

Authors:  Yi Y Zuo; Ruud A W Veldhuizen; A Wilhelm Neumann; Nils O Petersen; Fred Possmayer
Journal:  Biochim Biophys Acta       Date:  2008-04-08

Review 8.  Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions.

Authors:  Jesús Pérez-Gil
Journal:  Biochim Biophys Acta       Date:  2008-05-11

9.  Kinematic viscosity of therapeutic pulmonary surfactants with added polymers.

Authors:  Karen W Lu; Jesús Pérez-Gil; H William Taeusch
Journal:  Biochim Biophys Acta       Date:  2009-03

Review 10.  Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant.

Authors:  Odalys Blanco; Jesús Pérez-Gil
Journal:  Eur J Pharmacol       Date:  2007-04-30       Impact factor: 4.432

View more
  4 in total

1.  Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer.

Authors:  Elena López-Rodríguez; Olga Lucía Ospina; Mercedes Echaide; H William Taeusch; Jesús Pérez-Gil
Journal:  Biophys J       Date:  2012-10-02       Impact factor: 4.033

Review 2.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08

3.  Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.

Authors:  Yuliannis Lugones; Odalys Blanco; Elena López-Rodríguez; Mercedes Echaide; Antonio Cruz; Jesús Pérez-Gil
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

4.  New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs.

Authors:  Matthias Seehase; Jennifer J P Collins; Elke Kuypers; Reint K Jellema; Daan R M G Ophelders; Olga L Ospina; J Perez-Gil; Federico Bianco; Raffaella Garzia; Roberta Razzetti; Boris W Kramer
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.